AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03893565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
Trial: NCT00723723
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin
Trial: NCT02125253
Drug: Nasonex Nasal Spray, 50 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
Trial: NCT02125253
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a metered-dose, manual pump spray unit containing an aqueous suspension
Trial: NCT00128830
Drug: Nucleotide reverse transcriptase inhibitors (NRTIs)
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Trial: NCT00128830
Drug: Protease inhibitors (PIs)
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Trial: NCT01084174
Drug: Placebo extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered sublingually
Trial: NCT01084174
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered orally
Trial: NCT00708162
Drug: EVG placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match elvitegravir administered orally once daily
Trial: NCT00708162
Drug: RAL placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL placebo administered orally twice daily.
Trial: NCT04417621
Drug: LTT462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Trial: NCT00708162
Drug: Background regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
Trial: NCT00855179
Drug: Red vine leaf extract (AS 195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antistax film-coated tablet 360 mg
Trial: NCT00855179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to those containing Anstistax 360 mg
Trial: NCT00718913
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
Trial: NCT00718913
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
Trial: NCT06105827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give antibiotics or diclofenac sodium suppository as needed.
Trial: NCT06105827
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
Trial: NCT06105827
Drug: Combined group (Ningmitai plus tamsulosin)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
Trial: NCT02658838
Drug: full amount low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Trial: NCT02658838
Drug: half amount low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Trial: NCT02658838
Drug: No low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Trial: NCT02606539
Drug: Methotrexate plus folinic acid alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
Trial: NCT02368951
Drug: BAY1187982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
Trial: NCT02302547
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage treatment and usual prescription
Trial: NCT00563576
Drug: Femring®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months.
Trial: NCT00563576
Drug: DepoProvera ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
Trial: NCT01595386
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
Trial: NCT01595386
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
Trial: NCT00357084
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00503009
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02761005
Drug: Eradication of H. pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
Trial: NCT02952898
Drug: Diclofenac Sodium Gel, 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sodium gel, 3% is an FDA-approved drug.
Trial: NCT02952898
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
Trial: NCT01975727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of placebo (saline 0.9%)
Trial: NCT03444376
Drug: KEYTRUDA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab(100mg/4mL/vial), Intravenous administration
Trial: NCT00801580
Drug: doxorubicin liposomal
RxNorm normalized name: DOXOrubicin liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine
Trial: NCT02832180
Drug: OC containing EE and NET
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06016036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT01160172
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular vaccination according to protocol schedule
Trial: NCT01879930
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100
Trial: NCT04885153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
Trial: NCT04365218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
Trial: NCT00721630
Drug: capecitabine, lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
Trial: NCT00792935
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
Trial: NCT03925714
Drug: Nigetella salivata
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS twice daily
Trial: NCT04260555
Drug: DW1601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
Trial: NCT04260555
Drug: DW16011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
Trial: NCT04260555
Drug: DW16012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
Trial: NCT02183181
Drug: Meloxicam capsule
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183181
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02155543
Drug: AGN-223575 Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
Trial: NCT02155543
Drug: AGN-223575 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
Trial: NCT03665441
Drug: Irinotecan plus 5-FU plus leucovorin
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan, 5-FU, leucovorin
Trial: NCT05783830
Drug: ACD856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection 100 mcg
Trial: NCT00616798
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg po daily
Trial: NCT00616798
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg po daily
Trial: NCT00616798
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg po daily
Trial: NCT00616798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily
Trial: NCT00616798
Drug: Standard antipsychotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00871273
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
Trial: NCT01206101
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
Trial: NCT01258712
Drug: Tocilizumab + methotrexate(MTX)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
Trial: NCT00027248
Drug: MBI 226
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02475837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
Trial: NCT00152724
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00152724
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00152724
Drug: acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00152724
Drug: brethyllium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01009697
Drug: Codeine Sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg, 30 mg, and 60 mg tablets
Trial: NCT02538848
Drug: HTD4010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable solution
Trial: NCT04364425
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline
Trial: NCT02518516
Drug: Rosuvastatin (≥10 mg)
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT02518516
Drug: Simvastatin (≥40 mg)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT02518516
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT02518516
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT02518516
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT02518516
Drug: Simvastatin (<40 mg)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Trial: NCT03767335
Drug: MEN1611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle
Trial: NCT02053935
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
Trial: NCT02116608
Drug: Hydrocortisone Butyrate Cream, 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Trial: NCT03151408
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT00679601
Drug: AN2690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 7.5% Solution, once daily for 28 days
Trial: NCT02887456
Drug: Endodontic treatment using Vitapex
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment using Vitapex
Trial: NCT02887456
Drug: Endodontic treatment using MTA paste
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment using MTA paste
Trial: NCT03058094
Drug: AC0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg, orally, BID
Trial: NCT00003960
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01489631
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil 1mcg/ml